0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Metastatic Renal Cell Carcinoma (mRCC) - Epidemiology Forecast to 2028
Published Date: February 2019
|
Report Code: DELV-Epid-212
Home | Market Reports | Health | Health Conditions | Cancer
Metastatic Renal Cell Carcinoma Epidemiology Forecast to 2028

Metastatic Renal Cell Carcinoma (mRCC) - Epidemiology Forecast to 2028

Code: DELV-Epid-212
Report
February 2019
50 Pages
Delveinsight
Region: Global,
Description
Table of Content
Tables & Figures

DelveInsight's "Metastatic Renal Cell Carcinoma (mRCC) - Epidemiology Forecast, 2028” report provides a comprehensive analysis of the Metastatic Renal Cell Carcinoma (mRCC) epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2028

Metastatic Renal Cell Carcinoma (mRCC) Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Metastatic Renal Cell Carcinoma (mRCC) in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Metastatic Renal Cell Carcinoma (mRCC) outlook. It also includes the explanation of changing trends of epidemiology outlining the Metastatic Renal Cell Carcinoma (mRCC) scenario.

Metastatic Renal Cell Carcinoma (mRCC) Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Metastatic Renal Cell Carcinoma (mRCC) thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of Metastatic Renal Cell Carcinoma (mRCC) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Metastatic Renal Cell Carcinoma (mRCC) Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Metastatic Renal Cell Carcinoma (mRCC)

Key assessments
• Patient Segmentation in Metastatic Renal Cell Carcinoma (mRCC)
• Metastatic Renal Cell Carcinoma (mRCC) Risk & Burden
• Factors driving growth in a specific Metastatic Renal Cell Carcinoma (mRCC) patient population

1. Report Introduction
2. Metastatic Renal Cell Carcinoma (mRCC) Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Metastatic Renal Cell Carcinoma (mRCC) in 2016
2.2. Patient Share Distribution of Metastatic Renal Cell Carcinoma (mRCC) in 2028
3. Disease Background and Overview: Metastatic Renal Cell Carcinoma (mRCC)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Metastatic Renal Cell Carcinoma (mRCC) in 7MM
4.3. Total Prevalent/ Incident Patient Population of Metastatic Renal Cell Carcinoma (mRCC) in 7MM – By Countries
5. Epidemiology of Metastatic Renal Cell Carcinoma (mRCC) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC)
5.1.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) *
5.1.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) *
5.1.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC)
5.4.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) *
5.4.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) *
5.4.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC)
5.5.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) *
5.5.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) *
5.5.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC)
5.6.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) *
5.6.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) *
5.6.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC)
5.7.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) *
5.7.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) *
5.7.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC)
5.8.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) *
5.8.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) *
5.8.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC)
5.9.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) *
5.9.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) *
5.9.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC)
6. Unmet Needs of the Metastatic Renal Cell Carcinoma (mRCC)
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight

List of Table:

Table 1: Total Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in 7MM
Table 2: Total Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2028)*
Table 6: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2028) *
Table 13: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2028) *
Table 14: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2028) *
Table 26: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2028)

List of Figure:

Figure 1: Total Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2028) *
Figure 14: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2028)

SELECT A FORMAT
Added to Cart

Electronic (PDF)
$3250
This license allows only one user to access the PDF.

Electronic (PDF)
$6500
This license allows all the users of an enterprise residing in one location to access the PDF

Electronic (PDF)
$9750
This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Nano String

RELATED REPORTS

China Anti inflammatory Therapeutics Market Report Forecast 2021 2027
China Anti-inflammatory Therapeutics Market Report & Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-4J2573
Sat Oct 02 00:00:00 UTC 2021

Add to Cart

China Anti tumor Drug Market Report Forecast 2021 2027
China Anti-tumor Drug Market Report & Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-27N2168
Sat Oct 02 00:00:00 UTC 2021

Add to Cart

China Asparaginase Market Report Forecast 2021 2027
China Asparaginase Market Report & Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-9I393
Sat Oct 02 00:00:00 UTC 2021

Add to Cart

Global and United States Radiation Oncology Market Size Status and Forecast 2021 2027
Global and United States Radiation Oncology Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-18B3286
Mon Sep 27 00:00:00 UTC 2021

Add to Cart